Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

We conducted this study to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv). Cladribine 5.6 mg/m(2) given IV over 2 hours daily for 5 days was followed ∼ 1 month later with rituximab 375 mg/m(2) IV weekly...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ravandi, Farhad, O'Brien, Susan, Jorgensen, Jeffrey, Pierce, Sherry, Faderl, Stefan, Ferrajoli, Alessandra, Koller, Charles, Challagundla, Pramoda, York, Sergernne, Brandt, Mark, Luthra, Rajyalakshmi, Burger, Jan, Thomas, Deborah, Keating, Michael, Kantarjian, Hagop
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081440/
https://ncbi.nlm.nih.gov/pubmed/21821712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-351502
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados